TITLE:
Vaccines in Non-Small Cell Lung Cancer
AUTHORS:
Luis Corrales-Rodriguez, Normand Blais, Denis Soulières
KEYWORDS:
Emepepimut-S; Immunotherapy; Lung Cancer; MAGE-A3; NSCLC; Review; Vaccine
JOURNAL NAME:
World Journal of Vaccines,
Vol.3 No.1,
February
25,
2013
ABSTRACT:
Immunotherapy as an option
of treatment in cancer has experienced an important development with the
inclusion of vaccines. In lung cancer this type of treatment has emerged and
vaccines can be classified in three groups: antigen-specific vaccines, tumor cell vaccines,
and dendritic cell vaccines. Emepepimut (L-BLP25) and MAGE-A3 have been the
vaccines most widely studied. Their promising results with benefit in survival
and limited toxicity in preclinical and clinical trials have led to phase III trials with results eagerly
awaited. Other vaccines have been investigated, but results were not favorable
or are still pending. Hopefully, vaccines could be an additional instrument for
the treatment of lung cancer in the adjuvant or metastatic setting as time will
unveil the results of current and future trials.